The fourth ORBIS school strengthening international collaboration on pharmaceutical innovations was held in Prague

PRAGUE, September 16, 2022 /PRNewswire/ — Between 7e and 9e September, the fourth ORBIS School was held in prague. The event was co-organized by Zentiva in close collaboration with the German company Physiolution and the University of Chemistry and Technology of prague. Many various conferences and workshops took place during these three days and the participants had a great opportunity to share their experiences and knowledge based on their own research. Part of the program included a visit to Zentiva’s R&D department at its prague to place.

ORBIS 2022

ORBIS (Open Research Biopharmaceutical Internships Support) is an international project that is part of the European HORIZON 2020 program, focused on research and development. ORBIS is a platform that brings together universities, research institutes and pharmaceutical companies from several European countries.


Attendees from Ireland, France, Finland, Germany, Poland and Ukraine came to prague for the ORBIS school. Lectures and workshops at the University of Chemistry and Technology and the Czech Technical University focused on biopharmaceutical principles and new modern bioanalytical techniques or methods. The objective of the ORBIS project is to strengthen the link between the academic and industrial fields, to exchange expert knowledge and to create international partnerships through Europewhich can advance pharmaceutical research. “Innovations are a crucial part of what we do. At Zentiva, nearly 200 employees work in the R&D department. We support young talents and work to strengthen university-pharmaceutical industry cooperation. Joining the ORBIS project was an opportunity ideal for developing this type of cooperation at an international level. We believe that this type of partnership is the key to success,” said Pavel Šebek, Development Director of Zentiva. “Meeting other experts from different backgrounds is very enriching. It is always interesting to hear the experience of others and to discover new and original approaches to R&D. These events are always a great motivation.” said Nikita Marinkoa young and talented scientist from Zentiva who participated in this year’s ORBIS School and was part of the organizing team that took care of all the participants.

Of the four ORBIS schools that have taken place so far, two of them – the second and this one (the fourth) – were co-hosted by Zentiva. In September 2019in collaboration with the University of HelsinkiZentiva hosted the school covering pharmaceutical dosage form design and manufacturing processes, while new bio-relevant analytical approaches used in dosage form characterization were covered this September in prague. Both schools relied particularly on academic findings combined with concrete examples, these applied scientific approaches being appreciated by all participants.

The high number of participants confirmed the strength of the ORBIS scientific network and the focus on innovative approaches to meet currently unmet patient needs.

About ORBIS – Support for Open Research Biopharmaceutical Internships (Maria Skłodowska-Curie Actions of Horizon 2020 Framework Programme, H2020-MSCA-RISE-2017)

The primary objective of ORBIS is to form an international and intersectoral academic and industrial network. The action aims to improve the preclinical pathway of drug development by focusing on processes and technologies. The aim is to integrate multidisciplinary research by involving EU academia and industry (Poland, Ireland, Finland, Germanyand the Czech Republic), countries associated with the EU (Ukraine) and U.S. The project coordinator is Prof. Janina Lulek from Poznan University of Medical Sciences (Poland). Learn more about

About Zentiva

Zentiva is a producer of affordable, high-quality medicines serving the patients of Europe and beyond. With a dedicated team of over 4,700 people and a network of production sites – including flagship sites in prague, Bucharestand Ankleshwar – Zentiva strives to be the champion of branded and generic drugs in Europe to better meet people’s daily health care needs. At Zentiva, we want health care to be a right, not a privilege. More than ever, people need better access to affordable, high-quality medicines and health care. We partner with doctors, pharmacists, wholesalers, regulators and governments to provide the everyday solutions we all depend on. Visit us at

Media contact:

Mounira Lemoui
Communications Manager
U Kabelovny 529/16, Dolní Měcholupy, 102 00 Prague 10
Cell: (+420) 727 873 159 / Email: [email protected]

Photo –



Show original content to download multimedia: